

Sustainability disclosures and accounting metrics based on the Sustainability Accounting Standards Board (SASB) standards

For 2021 we have, for the first time, attempted to align our sustainability disclosures with those outlined in the relevant SASB Standards. As the nature of our business operations do not align absolutely with any of the standard industry definitions set out in the SASB Framework, we have based our disclosures on those elements of the Standards applicable to the Healthcare: Biotechnology & Pharmaceuticals, Healthcare: Distributors and Consumer Goods: Household & Personal Products sectors which we consider to be relevant to our business. Relevant accounting metrics, to the extent that these are available, and the location of related sustainability disclosures are set out in the table below.

Healthcare: Biotechnology & Pharmaceuticals

Table 1. Sustainability Disclosure Topics & Accounting Metrics

Topic	Code	Metric	2020	2021	Location of disclosures / Response
Safety of Clinical Trial Participants	HC-BP-210a.1	Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials	-	-	Not relevant to our business model (no involvement in clinical trials)
	HC-BP-210a.2	Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in: (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)	-	-	Not relevant to our business model (no involvement in clinical trials)
	HC-BP-210a.3	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	-	-	Not relevant to our business model (no involvement in clinical trials)
Access to Medicines	HC-BP-240a.1	Description of actions and initiatives to promote access to health care products for priority diseases and in priority countries as defined by the Access to Medicine Index	-	-	Limited relevance to our business model (no material sales of products for priority diseases / to priority countries)
	HC-BP-240a.2	List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)	-	-	Not relevant to our business model
Affordability & Pricing	HC-BP-240b.1	Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period	-	-	Not relevant to our business model
	HC-BP-240b.2	Percentage change in: (1) average list price and (2) average net price across U.S. product portfolio compared to previous year	Not reported	Not reported	Limited relevance to our business model (medicines portfolio comprises mature products and sales are primarily made in the UK where pricing is strictly controlled); no sales of medicines in the US
	HC-BP-240b.3	Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year	Not reported	Not reported	As above

Drug Safety	HC-BP-250a.1	List of products listed in the Food and Drug Administration's (FDA) MedWatch Safety Alerts for Human Medical Products database	Not reported	Not reported	
	HC-BP-250a.2	Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System	Not reported	Not reported	
	HC-BP-250a.3	Number of recalls issued, total units recalled	Not reported	Not reported	
	HC-BP-250a.4	Total amount of product accepted for takeback, reuse, or disposal	Not reported	Not reported	
	HC-BP-250a.5	Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type	See comments	See comments	See page 28, 2021 Annual Report – note that we have adapted the wording of this disclosure to make it more relevant to our business
Counterfeit Drugs	HC-BP-260a.1	Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting	-	-	Not reported
	HC-BP-260a.2	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	-	-	Not reported
	HC-BP-260a.3	Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products	Not reported	Not reported	
Ethical Marketing	HC-BP-270a.1	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	See comments	See comments	See page 28, 2021 Annual Report – note that we have adapted the wording of this disclosure to make it more relevant to our business
	HC-BP-270a.2	Description of code of ethics governing promotion of off-label use of products	-	-	See page 22, 2021 Annual Report – Ethical sales practices is one of the 'areas of focus' within our Sustainability Framework. See also: https://www.alliancepharmaceuticals.com/acting-responsibly/our-business-principles/
Employee Recruitment, Development & Retention	HC-BP-330a.1	Discussion of talent recruitment and retention efforts for scientists and research and development personnel	-	-	See page 22, 2021 Annual Report and also: https://www.alliancepharmaceuticals.com/acting-responsibly/people/ – note that our approach to recruitment and retention applies to all job roles company-wide, rather than by category.
	HC-BP-330a.2	(1) Voluntary and (2) involuntary turnover rate for: (a) executives/senior managers, (b) mid-level managers, (c) professionals, and (d) all others	See comments	See comments	See page 30, 2021 Annual Report – note that due to the relatively small number of heads in the business, voluntary / involuntary turnover rates are provided for the employee base as a whole, rather than by category
Supply Chain Management	HC-BP-430a.1	Percentage of (1) entity's facilities and (2) Tier I suppliers' facilities participating in the Rx-360 International Pharmaceutical Supply Chain	Not reported	Not reported	We do not maintain any of our own facilities – all manufacturing is outsourced.

		Consortium audit program or equivalent third-party audit programs for integrity of supply chain and ingredients			
Business Ethics	HC-BP-510a.1	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	£nil	£nil	See page 28, 2021 Annual Report – note that we have adopted the wider definition used in HC-DI-510a.2
	HC-BP-510a.2	Description of code of ethics governing interactions with health care professionals	-	-	See: https://www.alliancepharmaceuticals.com/acting-responsibly/our-business-principles/ See also: https://www.alliancepharmaceuticals.com/acting-responsibly/customers/ - transparency and public declarations

Healthcare: Distributors

Table 1. Sustainability Disclosure Topics & Accounting Metrics

Topic	Code	Metric	2020	2021	Location of disclosures / Response
Fleet Fuel Management	HC-DI-110a.1	Payload fuel economy	-	-	Not relevant to our business model (all logistics outsourced)
	HC-DI-110a.2	Description of efforts to reduce the environmental impact of logistics	-	-	See page 31, 2021 Annual Report
Product Safety	HC-DI-250a.1	Total amount of monetary losses as a result of legal proceedings associated with product safety	£nil	£nil	
	HC-DI-250a.2	Description of efforts to minimize health and safety risks of products sold associated with toxicity/chemical safety, high abuse potential, or delivery	-	-	Not reported specifically – however see: https://www.alliancepharmaceuticals.com/acting-responsibly/customers/ and https://www.alliancepharmaceuticals.com/acting-responsibly/our-business-principles/ for a more general overview of our approach to Product quality & safety – this is one of the ‘areas of focus’ within our Sustainability Framework – see page 28, 2021 Annual Report
Counterfeit Drugs	HC-DI-260a.1	Description of methods and technologies used to maintain traceability of products throughout the distribution chain and prevent counterfeiting	-	-	Brand protection and counterfeiting, primarily in relation to some of our more popular consumer products, is recognised as a risk within our Principal Risks and Uncertainties and appropriate mitigation measures have been put in place to counter this – see page 40, 2021 Annual Report
	HC-DI-260a.2	Discussion of due diligence process to qualify suppliers of drug products and medical equipment and devices	-	-	See page 28, 2021 Annual Report – Product quality and safety (which includes supplier qualification and assurance processes) is one of the ‘areas of focus’ within our Sustainability Framework See also: https://www.alliancepharmaceuticals.com/acting-responsibly/our-business-principles/

	HC-DI-260a.3	Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products	-	-	Not reported
Product Lifecycle Management	HC-DI-410a.1	Discussion of strategies to reduce the environmental impact of packaging throughout its lifecycle	-	-	See page 29, 2021 Annual Report – Packaging lifecycle management is one of the ‘areas of focus’ within our Sustainability Framework
	HC-DI-410a.2	Amount (by weight) of products accepted for take-back and reused, recycled, or donated	Not reported	Not reported	
Business Ethics	HC-DI-510a.1	Description of efforts to minimize conflicts of interest and unethical business practices	-	-	See page 28, 2021 Annual Report – Business ethics is one of the ‘areas of focus’ within our Sustainability Framework See also: https://www.alliancepharmaceuticals.com/acting-responsibly/our-business-principles/
	HC-DI-510a.2	Total amount of monetary losses as a result of legal proceedings associated with bribery, corruption, or other unethical business practices	£nil	£nil	See page 28, 2021 Annual Report

Consumer Goods: Household & Personal Products

Table 1. Sustainability Disclosure Topics & Accounting Metrics

Topic	Code	Metric	2020	2021	Location of disclosures / Response
Water Management	CG-HP-140a.1	(1) Total water withdrawn, (2) total water consumed, percentage of each in regions with High or Extremely High Baseline Water Stress	-	-	Not relevant to our business model (all manufacturing outsourced)
	CG-HP-140a.2	Description of water management risks and discussion of strategies and practices to mitigate those risks	-	-	Not relevant to our business model (all manufacturing outsourced)
Product Environmental, Health, and Safety Performance	CG-HP-250a.1	Revenue from products that contain REACH substances of very high concern (SVHC)	Not reported	Not reported	
	CG-HP-250a.1	Revenue from products that contain substances on the California DTSC Candidate Chemicals List	Not reported	Not reported	
	CG-HP-250a.1	Discussion of process to identify and manage emerging materials and chemicals of concern	-	-	See page 28, 2021 Annual Report – Product environmental health & safety is one of the ‘areas of focus’ within our Sustainability Framework
	CG-HP-250a.1	Revenue from products designed with green chemistry principles	Not reported	Not reported	
Packaging Lifecycle Management	CG-HP-410a.1	1) Total weight of packaging, (2) percentage made from recycled and/or renewable materials, and (3) percentage that is recyclable, reusable, and/or compostable	Not reported	Not reported	We do not currently have the capability to report this, however this is something we will be looking to report in future years, subject to the availability of relevant data

	CG-HP-410a.2	Discussion of strategies to reduce the environmental impact of packaging throughout its lifecycle	-	-	See page 29, 2021 Annual Report – Packaging Lifecycle Management is one of the ‘areas of focus’ within our Sustainability Framework
Environmental & Social Impacts of Palm Oil Supply Chain	CG-HP-430a.1	Amount of palm oil sourced, percentage certified through the Roundtable on Sustainable Palm Oil (RSPO) supply chains as (a) Identity Preserved, (b) Segregated, (c) Mass Balance, or (d) Book & Claim	Not reported	Not reported	

Table 2. Activity Metrics

Code	Metric	2020	2021	Location of disclosures / Response
CG-HP-000.A	Units of products sold, total weight of products sold	37.9m units	38.3m units	We do not currently have the capability to report total weight of product sold, however this is something we will be looking to report in future years, subject to the availability of relevant data
CG-HP-000.B	Number of manufacturing facilities	0	0	All manufacturing activities outsourced